Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).
Non-small Cell Lung Cancer
DRUG: Tarceva|RADIATION: Radiotherapy
Progression Free Survival, Progression free survival from registration according to RECIST 1.1, 3 years
Toxicity, 3 years|Local Tumor Control by CT-scan, May 2012|Overall Response Rate (CR + PR), May 2012|Local Tumor Control at 9 Months Evaluated by PET-CT, May 2012|Overall Survival, May 2012|Disease Free Survival, May 2012|Late Toxicity, May 2012
The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).